PL327617A1 - Compositions for and methods of treating osseous insufficiency - Google Patents

Compositions for and methods of treating osseous insufficiency

Info

Publication number
PL327617A1
PL327617A1 PL96327617A PL32761796A PL327617A1 PL 327617 A1 PL327617 A1 PL 327617A1 PL 96327617 A PL96327617 A PL 96327617A PL 32761796 A PL32761796 A PL 32761796A PL 327617 A1 PL327617 A1 PL 327617A1
Authority
PL
Poland
Prior art keywords
insufficiency
compositions
methods
treating osseous
osseous
Prior art date
Application number
PL96327617A
Inventor
Charles Petrie
Mark W Orme
Nand Baindur
Kirk G Robbins
Scott M Harris
Maria Kontoyianni
Laurence H Hurley
Sean M Kerwin
Gregory R Mundy
Original Assignee
Zymogenetics Inc
Osteoscreen
Univ Texas At Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Osteoscreen, Univ Texas At Austin filed Critical Zymogenetics Inc
Publication of PL327617A1 publication Critical patent/PL327617A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PL96327617A 1995-10-23 1996-10-23 Compositions for and methods of treating osseous insufficiency PL327617A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23

Publications (1)

Publication Number Publication Date
PL327617A1 true PL327617A1 (en) 1998-12-21

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96327617A PL327617A1 (en) 1995-10-23 1996-10-23 Compositions for and methods of treating osseous insufficiency

Country Status (13)

Country Link
EP (1) EP0866710A4 (en)
JP (1) JP2000513324A (en)
KR (1) KR19990067010A (en)
CN (1) CN1201393A (en)
AU (1) AU706262B2 (en)
BR (1) BR9611210A (en)
CA (1) CA2235481A1 (en)
CZ (1) CZ115398A3 (en)
EA (1) EA199800393A1 (en)
HU (1) HUP9802319A3 (en)
NO (1) NO981810L (en)
PL (1) PL327617A1 (en)
WO (1) WO1997015308A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9904567A3 (en) 1996-06-20 2001-10-29 Univ Texas Use of azo, thioalkyl, thiocarbonyl derivatives substituted by fused heterocycles and/or phenyl group for the preparation of pharmaceutical compositions stimulating bone growth
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
AU8748798A (en) * 1997-08-22 1999-03-16 Kyowa Hakko Kogyo Co. Ltd. 4-aminoquinazoline derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (en) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Use of extracts from Cimicifuga racemosa and Belamcanda sinensis as an estrogen-like organ-selective drug without uterotropic effects
JP2000004882A (en) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk Human MP52 gene promoter and method for searching for useful substances using the same
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
EP1127051A2 (en) * 1998-11-06 2001-08-29 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
AU5250400A (en) * 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
WO2001017562A1 (en) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
ATE305302T1 (en) * 1999-12-28 2005-10-15 Eisai Co Ltd HETEROCYCLIC COMPOUNDS WITH SULFONAMIDE GROUPS
FR2806408B1 (en) * 2000-03-17 2002-10-11 Oreal COSMETIC COMPOSITION COMPRISING A DERIVATIVE OF FURANE- NAPHTOQUINONE, THEIR USE AS COLORING AGENT AND DERIVATIVES
US7112680B2 (en) 2000-06-05 2006-09-26 Austria Wirtschaftsservice Gesellschaft Mit Beschrankter Haftung Heterocyclic hydrazones for use as anti-cancer agents
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
EP1500643A4 (en) * 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co BENZAMIDE DERIVATIVES
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES HAVING PRION PROTEIN ACCUMULATION AND METHOD OF MARKING
AU2003284492A1 (en) * 2002-12-16 2004-07-09 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
US20040192728A1 (en) 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
BRPI0510305A (en) 2004-04-30 2007-10-02 Takeda Pharmaceutical compound or a salt thereof, prodrug or a salt thereof, pharmaceutical agent, method of producing the compound or a salt thereof, matrix metalloproteinase inhibitor or a salt thereof or a prodrug thereof, method of inhibiting a metalloproteinase matrix, and use of a compound or salt thereof or a prodrug thereof
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
KR101629356B1 (en) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 Methods of preparing quinazolinone derivatives
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (en) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 Novel anti-inflammatory agents
RU2640115C2 (en) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Pharmaceutical compositions of substituted quinazolinones
WO2014012889A1 (en) 2012-07-18 2014-01-23 University College Dublin - National University Of Ireland, Dublin Anti-angiogenic compounds
CN102942515A (en) * 2012-10-22 2013-02-27 暨南大学 Ethane bridged indole compound, synthetic method and application thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
JO3789B1 (en) 2015-03-13 2021-01-31 Resverlogix Corp Compositions and therapeutic methods for the treatment of complement -associated diseases
CN107019687B (en) * 2017-05-08 2020-10-27 上海市伤骨科研究所 Application of N- (4-chlorphenyl) -3-hydroxy-2-naphthamide compound
CN111116552B (en) * 2020-01-17 2022-10-11 河北科技大学 Quinazolinone compound and preparation method thereof
CN114469863B (en) * 2021-11-26 2023-09-26 南方医科大学南方医院 Sterol liposomes as pulp and dentine drug delivery systems
CN116650481B (en) * 2021-12-10 2024-06-14 中南大学湘雅医院 Aromatic compounds as activators of plexin protein-B2 and their use in preparing drugs for treating osteoporosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2724396B2 (en) * 1987-12-18 1998-03-09 武田薬品工業株式会社 Osteoporosis prevention and treatment agent
WO1992000071A1 (en) * 1989-02-10 1992-01-09 Washington Research Foundation Immunoregulatory agents
JPH06192272A (en) * 1992-12-24 1994-07-12 Japan Tobacco Inc New triazolobenzothiadiazine and triazolobenzothiadiazepine derivative
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
EP0716086A1 (en) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Malonic acid based matrix metalloproteinase inhibitors
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2274789A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth

Also Published As

Publication number Publication date
CN1201393A (en) 1998-12-09
HUP9802319A3 (en) 1999-12-28
AU706262B2 (en) 1999-06-10
AU7471096A (en) 1997-05-15
EP0866710A4 (en) 2001-07-11
NO981810L (en) 1998-06-22
JP2000513324A (en) 2000-10-10
NO981810D0 (en) 1998-04-22
EP0866710A1 (en) 1998-09-30
WO1997015308A1 (en) 1997-05-01
BR9611210A (en) 1999-12-28
HUP9802319A2 (en) 1999-02-01
KR19990067010A (en) 1999-08-16
CZ115398A3 (en) 1998-12-16
EA199800393A1 (en) 1998-12-24
CA2235481A1 (en) 1997-05-01

Similar Documents

Publication Publication Date Title
PL327617A1 (en) Compositions for and methods of treating osseous insufficiency
PL324970A1 (en) Method of and composition for treating asthma
AU5439996A (en) Compositions and methods for treating pain
ZA977564B (en) Method of treatment
EP0693908A4 (en) Method and apparatus for installation of dental implant
EP0758242A4 (en) Composition and method for treatment of cmv infection
US5656608B1 (en) Amino acid compositions and methods of treatment using same
EP0933803A4 (en) Method of plasma treatment
GB9712866D0 (en) Novel method of treatment
PL327600A1 (en) Method of treating depressions
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
ZA963073B (en) Coating compositions and methods of using them
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
ZA973988B (en) Method of treatment
GB9507825D0 (en) Method of treatment
EP0763143A4 (en) Method of treating titanium parts
PL326924A1 (en) Compositions for and methods of preventing and treating mouth mucositis
AU7379296A (en) Method and composition for treatment of osteoporosis
GB9415902D0 (en) Method of treatment
EP0929540A4 (en) Antitumor compositions and methods of treatment
GB9407335D0 (en) Method of treatment
GB9414652D0 (en) Method of treatment
GB9523655D0 (en) Method of treatment
GB9516795D0 (en) Method of treatment
GB9508963D0 (en) Method of treatment